LP
ARQT icon

LMR Partners’s Arcutis Biotherapeutics ARQT Stock Holding History

LMR Partners’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-23,145
Closed -$322K – 1368
2024
Q4 		$322K Hold
23,145
– – ﹤0.01% 893
2024
Q3 		$215K Hold
23,145
– – ﹤0.01% 980
2024
Q2 		$215K Hold
23,145
– – ﹤0.01% 845
2024
Q1 		$229K Hold
23,145
– – ﹤0.01% 847
2023
Q4 		$74.8K Hold
23,145
– – ﹤0.01% 777
2023
Q3 		$123K Sell
23,145
-15,000
-39% -$128K ﹤0.01% 663
2023
Q2 		$364K Buy
38,145
+15,000
+65% +$166K ﹤0.01% 529
2023
Q1 		$255K Hold
23,145
– – ﹤0.01% 827
2022
Q4 		$343K Hold
23,145
– – 0.01% 935
2022
Q3 		$442K Hold
23,145
– – 0.01% 904
2022
Q2 		$493K Hold
23,145
– – 0.01% 913
2022
Q1 		$446K Hold
23,145
– – 0.01% 1015
2021
Q4 		$480K Hold
23,145
– – ﹤0.01% 925
2021
Q3 		$553K Buy
+23,145
New +$528K 0.01% 762

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LMR Partners's ARQT Position: Q1 2025 in Review

LMR Partners sold out of Arcutis Biotherapeutics (ARQT) in Q1 2025, closing a stake of 23,145 shares — an estimated $322K sold.

LMR Partners first reported a position in ARQT in Q3 2021 and held it in 14 quarters. The position peaked at $553K in Q3 2021. 241 funds tracked by Wall St. Rank hold ARQT as of Q1 2025.

  • LMR Partners reported no remaining Arcutis Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • LMR Partners sold 23,145 Arcutis Biotherapeutics shares in Q1 2025, an estimated $322K.
  • LMR Partners first reported a position in Arcutis Biotherapeutics in Q3 2021 and held it in 14 quarters.
  • LMR Partners's Arcutis Biotherapeutics position peaked at $553K in Q3 2021.
  • 241 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2025.

Based on LMR Partners's 13F filing for Q1 2025, filed 15 May 2025.